Toric IOLs good choice to correct astigmatism

Article

Residual astigmatism plays an important role in the quality of visual outcome after cataract surgery, so astigmatism correction must be targeted during cataract surgery. This is especially relevant in cases over 3 D of corneal astigmatism.

Residual astigmatism plays an important role in the quality of visual outcome after cataract surgery, so astigmatism correction must be targeted during cataract surgery. This is especially relevant in cases over 3 D of corneal astigmatism, said Jorge Alio, MD at the Acri.Tec symposium.

"Cataract surgery should not induce or change pre-existing astigmatism. It needs to be controlled, stable and precise and correction should not induce other optical changes, such as increased aberrations as this will cause a shift in the spherical correction of the eye," said Dr Alio.

Toric IOLs are a good choice because they offer full correction of the whole refractive error, and may correct for an unlimited amount of astigmatism.

Dr Alio outlined one cataract patient with preoperative UCVA counting fingers at 2 metres, with refraction of -4.5 sphere -6.5 and cylinder of 10. The patient underwent microincision cataract surgery (MICS) with Acri.Tec's Acri.Comfort 646 TLC implantation. The power was refraction +15.5, sphere +6.5 and cylinder of 100, achieving postoperative goal refraction of -0.27 sphere and -0.11 cylinder.

"Immediately, in the first postoperative day, the patient achieved 0.2 UCVA," said Dr Alio. "At three months postoperatively the patient had a UCVA 0.4, BCVA 0.5 with a refraction of 1, sphere -1 and cylinder 130," enthused Dr Alio.

The Acri.Comfort 646 is the only commercially available Toric MICS IOL, and it offers an unlimited amount of astigmatic correction during cataract surgery, according to Dr Alio. "Its rotational stability is excellent, and it gives outstanding refractive outcomes. It is the Toric pseudophakic IOL of choice in our clinic," he concluded.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.